PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Core Insights - The event hosted by PDS Biotechnology Corporation will focus on the changing landscape of recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC) in relation to Merck's KEYNOTE-689 study and the rising incidence of HPV16-positive HNSCC in the US and Europe [1][2] Company Overview - PDS Biotechnology is a late-stage immunotherapy company dedicated to transforming how the immune system targets and kills cancers, with a pivotal clinical trial underway for its lead program in advanced HPV16-positive HNSCC [7] Event Details - The virtual key opinion leader event will feature experts Kevin Harrington and Katharine A. Price discussing the unmet needs and treatment landscape for HPV16-positive HNSCC, including the investigational immunotherapy Versamune HPV [1][2][3] - The event is scheduled for June 17, 2025, from 12:00 PM to 1:30 PM ET [4] Treatment Landscape - The event will review the current treatment landscape for recurrent/metastatic HPV16-positive HNSCC, including the evaluation of Versamune HPV in a Phase 3 clinical trial in combination with pembrolizumab [2] - The discussion will highlight the distinction between HPV-positive and HPV-negative HNSCC, emphasizing their different underlying causes and treatment approaches [2]